TABLE 2.
Change of glycemic and lipid profile
| Sudachi | Placebo | t‐test | |||||
|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | Change | Baseline | 12 weeks | Change | ||
| Markers on glycemic control | |||||||
| HbA1c (%) | 5.56 ± 0.27 | 5.51 ± 0.28 | −0.05 | 5.69 ± 0.51 | 5.65 ± 0.47 | 0.039 | .0660 |
| Fasting glucose (mg/dl) | 91.80 ± 9.19 | 91.95 ± 10.45 | 0.15 | 91.44 ± 9.19 | 92.11 ± 6.93 | 0.67 | .3048 |
| Fasting insulin (uU/ml) | 6.01 ± 2.14 | 5.89 ± 3.11 | −0.21 | 7.21 ± 3.13 | 7.21 ± 3.13 | 0.017 | .6178 |
| HOMA IR | 1.40 ± 0.12 | 1.38 ± 0.17 | −0.15 | 1.64 ± 0.09 | 1.64 ± 0.09 | 0.002 | .8966 |
| HOMA β | 79.90 ± 7.65 | 77.04 ± 6.54 | −2.87 | 98.76 ± 5.87 | 98.76 ± 5.87 | −8.73 | .5340 |
| Lipid profile | |||||||
| Triglyceride (mg/dl) | 104.02 ± 44.21 | 113.6 ± 66.36 | 9.62 | 131.77 ± 31.24 | 172.88 ± 45.32 | 41.1 | .5976 |
| Total cholesterol (mg/dl) | 220.45 ± 32.57 | 215.55 ± 38.73 | −4.00 | 211.47 ± 35.87 | 207.04 ± 35.83 | −4.01 | .8116 |
| HDL cholesterol (mg/dl) | 60.15 ± 14.59 | 60.65 ± 15.67 | 0.22 | 59.67 ± 13.77 | 59.88 ± 14.85 | 0.22 | .8108 |
| LDL cholesterol (mg/dl) | 144.05 ± 19.34 | 140.02 ± 20.28 | −4.05 | 132.21 ± 17.28 | 123.72 ± 14.78 | −8.50 | .3885 |
| LDL‐C/HDL‐C | 2.52 ± 0.89 | 2.45 ± 0.91 | −0.07 | 2.36 ± 0.92 | 2.19 ± 0.99 | −0.16 | .3462 |
| Renal and hepatic markers | |||||||
| AST (IU/L) | 21.25 ± 15.11 | 20.36 ± 3.93 | −1.02 | 26.26 ± 7.77 | 25.28 ± 9.77 | −1.06 | .4658 |
| ALT (IU/L) | 27.72 ± 11.61 | 26.63 ± 13.4 | −2.42 | 26.94 ± 17.44 | 26.51 ± 12.75 | 0.45 | .4987 |
| BUN (mg/dl) | 15.03 ± 4.45 | 14.32 ± 3.48 | −0.17 | 12.25 ± 2.13 | 12.99 ± 3.02 | 0.79 | .1827 |
| Cre (mg/dl) | 0.68 ± 0.13 | 0.67 ± 0.14 | −0.01 | 0.70 ± 0.15 | 0.71 ± 0.16 | 0.01 | .3879 |